Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

AKRO Stock Forecast


Akero Therapeutics stock forecast is as follows: an average price target of $46.00 (represents a 43.53% upside from AKRO’s last price of $32.05) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AKRO Price Target


The average price target for Akero Therapeutics (AKRO) is $46.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $56.00 to $38.00. This represents a potential 43.53% upside from AKRO's last price of $32.05.

AKRO Analyst Ratings


Buy

According to 5 Wall Street analysts, Akero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AKRO stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Akero Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 17, 2024Ed ArceH.C. Wainwright$50.00$26.9785.39%56.01%
Jun 12, 2024Edward NashCanaccord Genuity$56.00$23.43139.01%74.73%
Jun 10, 2024Andy ChenWolfe Research$40.00$22.9973.99%24.80%
May 15, 2024Liisa BaykoEvercore ISI$38.00$20.3087.19%18.56%
Oct 11, 2023Ed ArceH.C. Wainwright$40.00$15.04165.96%24.80%
Sep 13, 2022Liisa BaykoEvercore ISI$50.00$29.0572.12%56.01%
Row per page
Go to

The latest Akero Therapeutics stock forecast, released on Sep 17, 2024 by Ed Arce from H.C. Wainwright, set a price target of $50.00, which represents a 85.39% increase from the stock price at the time of the forecast ($26.97), and a 56.01% increase from AKRO last price ($32.05).

Akero Therapeutics Price Target by Period


1M3M12M
# Anlaysts-14
Avg Price Target-$50.00$46.00
Last Closing Price$32.05$32.05$32.05
Upside/Downside-100.00%56.01%43.53%

In the current month, the average price target of Akero Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akero Therapeutics's last price of $32.05. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2024H.C. WainwrightBuyBuyHold
Jun 12, 2024Canaccord GenuityBuyBuyHold
Jun 10, 2024Wolfe Research-OutperformInitialise
May 15, 2024Evercore ISIOutperformOutperformHold
Sep 14, 2022Cantor Fitzgerald-OverweightInitialise
Row per page
Go to

Akero Therapeutics's last stock rating was published by H.C. Wainwright on Sep 17, 2024. The company gave AKRO a "Buy" rating, the same as its previous rate.

Akero Therapeutics Financial Forecast


Akero Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Akero Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKRO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Akero Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict AKRO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akero Therapeutics's previous annual EBITDA (undefined) of $NaN.

Akero Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-72.62M$-72.39M$-69.85M$-68.47M$-68.47M$-60.75M$-57.38M
High Forecast$-72.62M$-72.39M$-69.85M$-68.47M$-68.47M$-56.70M$-57.38M
Low Forecast$-72.62M$-72.39M$-69.85M$-68.47M$-68.47M$-68.17M$-57.38M
Surprise %-------

Akero Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKRO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Akero Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Akero Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKRO last annual SG&A of $NaN (undefined).

Akero Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-1.05$-1.05$-1.01$-0.99$-0.99$-0.88$-0.83
High Forecast$-1.05$-1.05$-1.01$-0.99$-0.99$-0.82$-0.83
Low Forecast$-1.05$-1.05$-1.01$-0.99$-0.99$-0.99$-0.83
Surprise %-------

According to undefined Wall Street analysts, Akero Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKRO previous annual EPS of $NaN (undefined).

Akero Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.60$6.00900.00%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
VKTXViking Therapeutics$63.14$100.5059.17%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
RNAAvidity Biosciences$44.82$54.5021.60%Buy
PTGXProtagonist Therapeutics$46.76$50.006.93%Buy
RVMDRevolution Medicines, Inc. Warrant$55.87$58.574.83%Buy
MDGLMadrigal Pharmaceuticals$331.32$315.75-4.70%Buy

AKRO Forecast FAQ


Yes, according to 5 Wall Street analysts, Akero Therapeutics (AKRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AKRO's total ratings.

Akero Therapeutics (AKRO) average price target is $46 with a range of $38 to $56, implying a 43.53% from its last price of $32.05. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AKRO stock, the company can go up by 43.53% (from the last price of $32.05 to the average price target of $46), up by 74.73% based on the highest stock price target, and up by 18.56% based on the lowest stock price target.

AKRO's highest twelve months analyst stock price target of $56 supports the claim that Akero Therapeutics can reach $50 in the near future.

Akero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-187M (high $-183M, low $-194M), average SG&A $0 (high $0, low $0), and average EPS is $-2.698 (high $-2.639, low $-2.805). AKRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-283M (high $-283M, low $-283M), average SG&A $0 (high $0, low $0), and average EPS is $-4.097 (high $-4.097, low $-4.097).